New GPER1 Research Offers Hope for Chronic Skin Inflammation Treatment

New research highlights the potential of GPER1, a G protein-coupled estrogen receptor, in treating chronic skin inflammation. Scientists have discovered that this receptor plays a key role in slowing down the excessive growth of skin cells, a hallmark of conditions like psoriasis. The findings suggest a more targeted approach to therapy, which could offer safer alternatives to current treatments.

GPER1 works differently from traditional estrogen receptors by triggering rapid cellular responses. Its activation significantly reduces keratinocyte proliferation, especially during the G1 phase of the cell cycle. This effect is linked to its interference with the MAPK/ERK pathway, which lowers the production of inflammatory markers such as TNF-α and IL-6.

In animal studies, GPER1 agonists have shown promise in easing psoriasis-like symptoms. Disease severity and skin inflammation markers improved, pointing to the receptor's therapeutic potential. However, as of March 2026, no clinical trials for GPER1-based treatments in humans have been registered. Preclinical research exists, but no studies have progressed to Phase 1–3 testing. The broader implications of this work extend beyond inflammation control. Assessing GPER1 levels in patients could help tailor treatments, aligning with the growing field of personalised medicine. Additionally, the study reinforces the importance of G protein-coupled receptors in skin health and disease, opening doors for future drug development.

While clinical applications remain in early stages, the discovery of GPER1's inhibitory effects on keratinocyte growth provides a foundation for new therapies. If successfully developed, GPER1 agonists could become a novel class of topical or systemic treatments for inflammatory skin diseases. This could eventually lead to better disease management and improved outcomes for affected patients.